The London Neuropsychiatry Clinic

Updated 21 October 2025

Date of Assessment: 5 and 6 August 2025.

The London Neuropsychiatry Clinic is an independent service delivering community mental health interventions. The London Neuropsychiatry Clinic is delivered by a single Neuropsychiatrist; Dr Bodani, and their personal assistant. The London Neuropsychiatry Clinic provides a neuropsychiatry consultation service with referrals from GP’s and other consultants, brain injury case managers or self-referrals from patients.

Following this assessment, the location was rated as good.

The London Neuropsychiatry Clinic registered with the Care Quality Commission in May 2024 to provide treatment of disease, disorder or injury.

Consultations are offered either face to face at 96 Harley Street London, or where necessary remotely using secure digital platforms.

This is our initial comprehensive inspection of the service. We rated it as good overall.

We found several areas of good practice:

Staff delivered person-centred care and developed tailored services in partnership with people.

Staff developed holistic, recovery-oriented care plans informed by a comprehensive assessment.

Staff treated patients with compassion and kindness and understood the individual needs of patients. They actively engaged patients in decisions about their care, ensuring that planning was collaborative and person-centred.

Patients told us that their experience was prompt and supportive, and reasonable adjustments were made according to need.

We found some areas for improvement:

The administrative staff supported the triage of patients and spoke to patients regularly about their medication, wellbeing and at times during deteriorating mental health.

The Multi-Disciplinary Team meeting minutes did not reflect whether the Neuropsychiatrist was discussing the choice of preparation, dose and follow up arrangements as part of the review.

The service did not carry out patient records and prescribing audits to ensure safe prescribing was taking place.

The prescribing policies did not contain information about inclusion, and exclusion criteria for cannabis based medicinal products (CBPMs).

Patients could give feedback on the service, via the provider website, however there was no formal and regular mechanism to obtain feedback consistently to help improve the service.

Updated 15 July 2025

We carried out an announced comprehensive inspection at The London Neuropsychiatry Clinic as part of our inspection programme.

The London Neuropsychiatry Clinic is an independent service delivering community mental health interventions. The London Neuropsychiatry Clinic is delivered by a single Neuropsychiatrist; Dr Bodani, and their personal assistant. The London Neuropsychiatry Clinic provides a neuropsychiatry consultation service with referrals from GP’s and other consultants, brain injury case managers or self-referrals from patients.

The service also offers domiciliary consultation where required which can be for clinical assessment, second opinion on diagnosis or follow up care. Assessments are carried out in the patient's home by consent with a carer present; in care homes; in nursing homes; in hospitals if necessary; or at the GP surgery by prior arrangement.

At the time of the assessment, 30 patients were receiving treatment at the service.

The service was registered in May 2024, and this was our first inspection of the service.

At this assessment we rated the service as good. We spoke with 4 patients and 5 carers. We also reviewed the care and treatment records of 14 patients.

At this assessment we found several areas of good practice. The service developed holistic, recovery-oriented care plans informed by a comprehensive assessment.

We saw evidence of patient centred discussions in Multi-Disciplinary Team (MDT) meetings. The neuropsychiatrist was actively involved in a peer review group at the Maudsley Hospital, contributing to the oversight of prescribing practices through structured case reviews. As part of an independent prescriber’s peer group, they collaborated with consultants and specialists in cannabis-based treatment, meeting quarterly in person to review patient cases and ensure prescribing decisions were clinically sound and patient-centred. The neuropsychiatrist also participated in Multidisciplinary Team (MDT) meetings with other cannabis prescribers, where they regularly presented case studies to support shared learning and uphold high standards of care.

We saw evidence of discussions with patients during their appointment which were used to inform decisions about diagnosis and treatment.

Feedback from the staff was very positive. Staff described a safe working environment with the freedom to speak up, emphasising an open and transparent culture, and their enjoyment of working at this service.

Staff treated patients with compassion and kindness and understood the individual needs of patients. They actively involved patients in decisions and planning their care.

The environment was generally well-furnished, safe and clean.

Carers told us that the service was exceptional. Carers told us that they were happy with the service, and they felt involved in care decisions.

Patients told us that their experience was prompt and supportive, and reasonable adjustments were made according to need.

However, we did find areas of improvement, and we found breaches of regulation in relation to Good Governance and Staffing.

The Multi-Disciplinary Team meetings (MDT) meeting minutes did not reflect whether the psychiatrist was discussing the choice of preparation, dose and follow up arrangements as part of patient review, for those prescribed a particular medicine.

The service did not carry out patient records and prescribing audits to ensure safe prescribing was taking place.

Administrative staff had not had the full range of training or supervision to support their role in supporting patient triage and maintained regular contact with individuals regarding their medication, wellbeing, and during periods of deteriorating mental health. While an escalation protocol was in place, it relied on administrative staff identifying and passing on concerns from telephone calls to the Psychiatrist, who also serves as the Registered Manager. This approach may limit the effectiveness of early intervention, particularly in safeguarding matters.

There were several service policies that expired in June 2024.

The prescribing policies did not contain information about inclusion and exclusion criteria for cannabis based medicinal products (CBPMs).

Patients could give feedback on the service, via the provider website, however there was no formal and regular mechanism to obtain feedback consistently to help improve the service.

We have asked the provider for an action plan in response to the concerns found at this assessment.